IMARC Group has recently released a new research study titled “United States Biosimilar Market Size, Share, Trends and Forecast by Molecule, Manufacturing Type, Indication, and Region, 2026-2034”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

Market Overview

The United States biosimilar market size was valued at USD 7.7 Billion in 2025 and is projected to reach USD 33.2 Billion by 2034, growing at a CAGR of 17.60% during 2026-2034. This growth is driven by rising demand for cost-effective treatments for chronic diseases like cancer and diabetes, supportive FDA policies, and increasing strategic collaborations among pharmaceutical companies. The market outlook includes enhanced affordability, accessibility, and adoption of biosimilars in the healthcare system.

Study Assumption Years

●     Base Year: 2025

●     Historical Year/Period: 2020-2025

●     Forecast Year/Period: 2026-2034

United States Biosimilar Market Key Takeaways

●     Current Market Size: USD 7.7 Billion in 2025

●     CAGR: 17.60% (2026-2034)

●     Forecast Period: 2026-2034

●     The market is driven by increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders.

●     Rising efforts to reduce healthcare costs and patent expirations of biologics are opening the biosimilar market.

●     FDA policy reforms like the Biosimilar User Fee Act (BsUFA) are streamlining biosimilar approvals.

●     Educational programs and strategic collaborations are enhancing biosimilar adoption and accessibility.

●     Biosimilar portfolios are expanding into rare diseases, ophthalmology, and hormonal therapies.

●     Pharmacy-level substitution policies and insurer formulary revisions support biosimilar demand.

Sample Request Link: https://www.imarcgroup.com/united-states-biosimilar-market/requestsample

United States Biosimilar Market Growth Factors

The biosimilar market growth in the United States is significantly driven by the rising prevalence of chronic diseases including cancer, diabetes, and autoimmune disorders, necessitating cost-effective biologic treatments. According to a 2024 report by the National Center for Chronic Disease Prevention and Health Promotion, approximately 129 million Americans have one or more major chronic conditions, with 42% having two or more, and 12% five or more. These chronic diseases account for 90% of the annual USD 4.1 trillion health care costs in the U.S. Biosimilars, offering comparable efficacy and safety at significantly reduced prices, are adopted as cost-saving alternatives.

Patent expirations for several high-revenue biologics are creating market opportunities for biosimilar manufacturers. FDA policy reforms such as the Biosimilar User Fee Act (BsUFA) are streamlining regulatory pathways, making approval processes quicker and less burdensome. Additionally, increasing focus on lowering healthcare expenditures is spurring adoption as insurers and healthcare providers prioritize affordable options. Educational initiatives aimed at healthcare professionals and patients also improve confidence in these alternatives.

Strategic collaborations between biosimilar manufacturers and pharmaceutical companies further accelerate market entry and increase accessibility. For example, the acquisition of CIMERLI by Sandoz in April 2024 expanded ophthalmology biosimilar portfolios and improved low-cost treatment access for retinal diseases. Other supportive factors include a regulatory-friendly environment, rising disposable incomes, and growing public awareness, all contributing towards a positive biosimilar market outlook.

To get more information on this market, Request Sample

United States Biosimilar Market Segmentation

Breakup by Molecule:

●     Infliximab: Widely used for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis; gaining acceptance due to similar efficacy and cost-effectiveness.

●     Insulin Glargine: Important for diabetes management; biosimilars offer an affordable alternative to branded long-acting insulins.

●     Epoetin Alfa: Used for anemia due to chronic kidney disease and cancer; popular for cost-effectiveness and therapeutic equivalence.

●     Etanercept

●     Filgrastim

●     Somatropin

●     Rituximab

●     Follitropin Alfa

●     Adalimumab

●     Pegfilgrastim

●     Trastuzumab

●     Bevacizumab

●     Others

Breakup by Manufacturing Type:

●     In-house Manufacturing: Preferred by companies with sufficient infrastructure; ensures better control of quality, cost, timelines, and intellectual property.

●     Contract Manufacturing: Popular among small and medium biosimilar companies; reduces operational risk and cuts costs by outsourcing to specialized third-party manufacturers.

Breakup by Indication:

●     Auto-Immune Diseases: Holds major market share; reduced treatment costs with biosimilars like infliximab and adalimumab; increasing prevalence boosts growth.

●     Blood Disorder: Biosimilars like epoetin alfa and filgrastim improve anemia and neutropenia treatment; demand fueled by advancements and cost containment efforts.

●     Diabetes: Rapid growth due to rising diabetes rates; biosimilars for insulin glargine provide accessible, cost-effective long-term management.

●     Oncology

●     Growth Deficiency

●     Female Infertility

●     Others

Regional Insights

The Northeast leads in biosimilar adoption owing to advanced healthcare infrastructure, a strong pharmaceutical industry, and policy-driven cost-control measures, particularly in states like New York and Massachusetts. This support, along with heightened awareness among healthcare professionals and patients, drives substantial market growth. The Midwest, South, and West regions show steady to rapid expansion, with factors such as increased insurance coverage, chronic disease prevalence, biotechnology hubs, and regulatory advances contributing to the overall market development.

Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=11073&flag=C

Recent Developments & News

●     September 30, 2024: Fresenius Kabi and Formycon announced FDA approval of Otulfi (ustekinumab-aauz), a biosimilar for inflammatory diseases; it will be Fresenius Kabi's fourth US biosimilar.

●     May 21, 2024: Biocon Biologics received FDA approval for YESAFILI (aflibercept), the first interchangeable biosimilar to Eylea in the US ophthalmology market.

●     April 16, 2024: Alvotech and Teva Pharmaceuticals announced FDA approval of SELARSDI (ustekinumab-aekn) for plaque psoriasis and psoriatic arthritis; commercialization to begin early next year.

●     December 3, 2024: Accord BioPharma agreed to purchase UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences; UDENYCA generated USD 127.1 million in sales in 2023.

Key Players

●     Sandoz International GmbH

●     Pfizer Inc.

●     Teva Pharmaceutical Industries Limited

●     Celltrion Inc.

●     Biocon Biologics Ltd

●     Samsung Biologics

●     Amgen, Inc.

●     Dr. Reddy's Laboratories Limited

●     Fresenius Kabi USA

●     Chugai Pharmaceutical Co., Ltd.

Competitive Landscape

The market research report covers a comprehensive competitive landscape analysis including market structure, key player positioning, winning strategies, competitive dashboards, and company evaluation quadrants. Detailed profiles of all major companies have been provided.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302